Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Express Scripts
Mallinckrodt
McKesson

Last Updated: September 26, 2022

SUPRANE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Suprane patents expire, and when can generic versions of Suprane launch?

Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the desflurane profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Suprane

A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26th, 2018.

  Sign up for a Free Trial

Drug patent expirations by year for SUPRANE
Drug Prices for SUPRANE

See drug prices for SUPRANE

Recent Clinical Trials for SUPRANE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute, EgyptN/A
Sefako Makgatho Health Sciences UniversityN/A
G√úNER KAYAN/A

See all SUPRANE clinical trials

Pharmacology for SUPRANE
Drug Class General Anesthetic
Physiological EffectGeneral Anesthesia
Anatomical Therapeutic Chemical (ATC) Classes for SUPRANE
Paragraph IV (Patent) Challenges for SUPRANE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SUPRANE Inhalation desflurane 99.9% 020118 1 2008-09-11

US Patents and Regulatory Information for SUPRANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare SUPRANE desflurane LIQUID;INHALATION 020118-001 Sep 18, 1992 AN RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUPRANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare SUPRANE desflurane LIQUID;INHALATION 020118-001 Sep 18, 1992 See Plans and Pricing See Plans and Pricing
Baxter Hlthcare SUPRANE desflurane LIQUID;INHALATION 020118-001 Sep 18, 1992 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SUPRANE

See the table below for patents covering SUPRANE around the world.

Country Patent Number Title Estimated Expiration
Denmark 170207 See Plans and Pricing
Finland 107997 See Plans and Pricing
Japan 3324750 See Plans and Pricing
World Intellectual Property Organization (WIPO) 9212752 See Plans and Pricing
South Korea 100198205 See Plans and Pricing
South Korea 910006888 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SUPRANE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0285237 94C0006 France See Plans and Pricing PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
0285237 95C0008 Belgium See Plans and Pricing PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Boehringer Ingelheim
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.